A way to live with disease without sacrificing long-term health
For a subset of severe asthma patients, daily survival has long meant trading one harm for another — steroids that open airways while quietly eroding bones, heart, and metabolic health. The Phase 3 SUNRISE trial, published in The Lancet Respiratory Medicine, suggests that tezepelumab may finally offer these patients a path that does not demand such a toll. In a population for whom conventional medicine had run out of answers, nearly seven in ten were able to cut their steroid burden in half, and more than a third stepped away from oral corticosteroids entirely.
- Severe asthma patients dependent on daily oral steroids face a slow-motion health crisis — the very drugs keeping them breathing are causing diabetes, fractures, and heart damage over time.
- The SUNRISE trial enrolled adults already on maximum inhaled therapy, testing whether tezepelumab could break the steroid dependence that standard treatment could not.
- Tezepelumab-treated patients were nearly three times more likely to cut steroid doses by half compared to placebo, with 35% stopping oral corticosteroids altogether versus just 21% on placebo.
- The trial's gold-standard design — randomized, double-blind, placebo-controlled over 28 weeks — lends the results significant clinical weight in a field hungry for alternatives.
- The findings are now circulating through the medical community, but the real test lies ahead: whether access barriers and insurance coverage will allow these results to reach the patients who need them most.
For people with severe asthma who depend on daily oral corticosteroids just to breathe, the treatment itself becomes a source of harm. Years of steroid use can trigger diabetes, weaken bones, and damage the cardiovascular system — a slow erosion of health traded for the ability to breathe. A new clinical trial suggests that trade may no longer be inevitable.
The Phase 3 SUNRISE trial tested tezepelumab in adults with severe, corticosteroid-dependent asthma who had already exhausted high-dose inhaled therapies. Over 28 weeks, 69% of patients receiving tezepelumab reduced their daily steroid dose by at least half while maintaining asthma control — compared to 44% in the placebo group. More strikingly, 35% of tezepelumab patients stopped oral corticosteroids entirely, versus 21% on placebo.
Lead investigator Michael Wechsler of National Jewish Health described the significance in direct terms: for patients trapped in steroid dependence, reducing or eliminating these medications without losing control of their breathing represents a fundamental shift. The complications of long-term steroid use are not minor inconveniences — they are serious, progressive, and often irreversible.
What distinguishes this trial is its focus on a population often left behind by other asthma advances. These patients have nowhere left to turn within conventional treatment. Tezepelumab doesn't offer a cure, but it offers a way to live with severe asthma without surrendering long-term health to manage daily breathing. The results, now published in The Lancet Respiratory Medicine, raise an urgent practical question: how quickly can this option reach the patients who need it, and will access and coverage barriers stand in the way.
For people with severe asthma who wake each morning and swallow oral corticosteroids just to breathe, the drugs that keep their airways open come with a steep price. Years of relying on these steroids can trigger diabetes, weaken bones until they fracture, damage the heart. The quality of life erodes alongside the body. But a new clinical trial offers something these patients have rarely had: a way out.
The Phase 3 SUNRISE trial, results now published in The Lancet Respiratory Medicine, tested a drug called tezepelumab in adults with severe asthma who depend on daily oral corticosteroids despite already taking high-dose inhaled treatments. These are patients for whom standard therapy has failed. The study was randomized, double-blind, placebo-controlled—the gold standard of clinical evidence. Over 28 weeks, researchers tracked what happened when tezepelumab was added to their regimen.
The numbers tell a story of meaningful relief. Among patients receiving tezepelumab, 69 percent managed to cut their daily oral corticosteroid dose by at least half while keeping their asthma under control. In the placebo group, only 44 percent achieved the same reduction. That's nearly a threefold difference in the likelihood of substantial steroid reduction. Even more striking: 35 percent of those on tezepelumab were able to stop taking oral corticosteroids altogether. In the placebo arm, just 21 percent reached that milestone.
Michael Wechsler, who led the study as director of the Cohen Family Asthma Institute at National Jewish Health, framed the significance plainly. For patients trapped in steroid dependence, the ability to reduce or eliminate these medications while maintaining asthma control represents a fundamental shift in what's possible. The long-term complications of oral corticosteroid use—diabetes, osteoporosis, cardiovascular disease, the cumulative toll on daily life—are not minor side effects. They are serious, progressive, and often irreversible. A drug that allows patients to step away from that dependence without losing control of their breathing changes the calculus of their treatment entirely.
What makes this trial particularly valuable is that it addresses a population often left behind by other asthma breakthroughs. Patients with severe, corticosteroid-dependent asthma are a small subset, but their need is acute. They are already on maximum inhaled therapy. They have nowhere else to turn within the conventional toolkit. Tezepelumab offers them a new option—not a cure, but a way to live with their disease that doesn't require sacrificing their long-term health to manage their breathing.
The findings suggest that tezepelumab could reshape treatment pathways for this group. As the results circulate through the medical community, the question now becomes how quickly the drug reaches patients who need it, and whether insurance coverage and access barriers will allow those benefits to translate into real-world practice. For people who have spent years balancing asthma control against the slow accumulation of steroid-related damage, the SUNRISE trial offers something that has been scarce: genuine hope for a different way forward.
Citas Notables
Patients with severe asthma treated with tezepelumab may be able to substantially reduce their dependence on oral steroids without sacrificing asthma control.— Michael Wechsler, MD, director of the Cohen Family Asthma Institute at National Jewish Health
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter so much that patients can reduce steroids while keeping asthma controlled? Couldn't they just accept the side effects?
Because the side effects aren't minor inconveniences—they're progressive, often permanent damage. A 40-year-old on long-term oral steroids is building toward diabetes, fractures, heart disease. You're trading one disease for others.
So tezepelumab is solving a problem that other asthma drugs haven't touched?
Exactly. Most asthma treatments work on the inflammation in the airways. But for patients already maxed out on those, the only option was oral steroids. Tezepelumab works differently—it targets a pathway that lets some patients finally step away from the steroids.
The numbers show 69 percent got a 50 percent reduction. What about the other 31 percent?
That's the honest part. It doesn't work for everyone. But even partial reductions matter. Cutting your steroid dose in half still means less diabetes risk, less bone loss. And 35 percent stopping entirely—that's transformative for those people.
Is this a cure?
No. These patients still have severe asthma. They'll likely need tezepelumab long-term. But it's the difference between managing a disease and being slowly damaged by the treatment. That's not nothing.
What happens next? Do patients get access immediately?
That's the real test. The trial proves it works. Now comes insurance coverage, manufacturing scale, getting it to the clinics where these patients actually receive care. The science is solid. The access question is harder.